AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28836285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction (OHI), scaling and root debridement (n = 11)
Number of subjects: 18
Study 28836285 — intervention group
Group type: COMPARATOR
Intervention: OHI alone (Control group, n = 7)
Number of subjects: 18
Study 26024110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 56
Study 26024110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 56
Study 26024110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 56
Study 26024110 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 23323608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sander bite-jumping appliance (BJA)
Number of subjects: 46
Study 23323608 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 46
Study 21136011 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 30 mg qd
Number of subjects: 235
Study 21136011 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 60 mg qd
Number of subjects: 235
Study 21136011 — intervention group
Group type: COMPARATOR
Intervention: warfarin (dose adjusted to INR of 2-3)
Number of subjects: 235
Study 21136011 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 235
Study 20301881 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 30
Study 20301881 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 30
Study 17875844 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide excision margins
Number of subjects: 3313
Study 17875844 — intervention group
Group type: COMPARATOR
Intervention: Narrow excision margins
Number of subjects: 3313
Study 15138774 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 52
Study 15138774 — intervention group
Group type: COMPARATOR
Intervention: Parapatellar approach
Number of subjects: 52
Study 15138774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenting visual acuity worse than 6/60 in both eyes
Number of subjects: 4284
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity worse than 6/60 in both eyes
Number of subjects: 4284
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract as the principal cause of blindness
Number of subjects: 4284
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected aphakia and other refractive error
Number of subjects: 4284
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery prevalence
Number of subjects: 4284
Study 11297483 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical coverage for cataract blind
Number of subjects: 4284
Study 9669432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate Dialysis (AD)
Number of subjects: 5
Study 9669432 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate Dialysis (BD)
Number of subjects: 5
Study 9669432 — intervention group
Group type: COMPARATOR
Intervention: Acetate-Free Biofiltration (AFB)
Number of subjects: 5
Study 8145632 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based interview
Number of subjects: 294
Study 8145632 — intervention group
Group type: COMPARATOR
Intervention: Standard American Red Cross procedures (written questionnaires and face-to-face interviews)
Number of subjects: 294
Study 3206202 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days with oral hygiene measures (toothbrush, toothpaste, dental floss)
Number of subjects: 12
Study 3206202 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days without oral hygiene measures
Number of subjects: 12
Study 30143705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 64
Study 30143705 — intervention group
Group type: COMPARATOR
Intervention: Control (usual sodium intake)
Number of subjects: 64
Study 27044574 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting suture
Number of subjects: 320
Study 27044574 — intervention group
Group type: COMPARATOR
Intervention: Conventional closure with drainage
Number of subjects: 320
Study 25831645 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25‐hydroxy vitamin D levels in cases
Number of subjects: 169
Study 25831645 — intervention group
Group type: COMPARATOR
Intervention: Serum 25‐hydroxy vitamin D levels in controls
Number of subjects: 169
Study 25831645 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathormone and calcium levels in cases
Number of subjects: 169
Study 25831645 — intervention group
Group type: COMPARATOR
Intervention: Parathormone and calcium levels in controls
Number of subjects: 169
Study 23311969 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention for parents of children with cancer
Number of subjects: 0
Study 21391414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reframing (CR) coping strategies
Number of subjects: 45
Study 21391414 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct assistance (DA) coping strategies
Number of subjects: 45
Study 21391414 — intervention group
Group type: EXPERIMENTAL
Intervention: Existential well-being
Number of subjects: 45
Study 21391414 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific coping strategies related to DSED
Number of subjects: 45
Study 18430174 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures
Number of subjects: 59
Study 18430174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quilting sutures)
Number of subjects: 59
Study 15723742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (237 mL/d of 4 or 8 kJ/mL) for 4 weeks
Number of subjects: 50
Study 15723742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 12828863 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ICAM-1
Number of subjects: 0
Study 12828863 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 11110008 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (active drug)
Number of subjects: 222
Study 11110008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 222
Study 8665186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hexylcarbamoyl-5-fluorouracil (HCFU)
Number of subjects: 67
Study 8665186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HCFU)
Number of subjects: 67
Study 2005733 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 g of oatmeal
Number of subjects: 156
Study 2005733 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 g of oat bran
Number of subjects: 156
Study 2005733 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 g of oat bran
Number of subjects: 156
Study 2005733 — intervention group
Group type: EXPERIMENTAL
Intervention: 56 g of oatmeal
Number of subjects: 156
Study 2005733 — intervention group
Group type: COMPARATOR
Intervention: 28 g of farina (beta-glucan control)
Number of subjects: 156
Study 6824299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous bupivacaine injection around the wound
Number of subjects: 0
Study 30237505 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 500 mg/day
Number of subjects: 192
Study 30237505 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 40 mg/day
Number of subjects: 192
Study 30237505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 26773778 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified limonin glucoside (LG)
Number of subjects: 10
Study 26773778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24448847 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook application for smoking cessation with various components (expanded content, proactive contact, active and passive sharing, use by non-smoker supporters)
Number of subjects: 0
Study 24448847 — intervention group
Group type: COMPARATOR
Intervention: Reference group (baseline R0)
Number of subjects: 0
Study 21527434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Package B
Number of subjects: 14
Study 21527434 — intervention group
Group type: COMPARATOR
Intervention: Intervention Package A
Number of subjects: 14
Study 20534325 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine-supplemented (10 mg/[kg d])
Number of subjects: 25
Study 20534325 — intervention group
Group type: COMPARATOR
Intervention: Control (LCNS)
Number of subjects: 25
Study 18723821 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based/problem-based (CB/PB) teaching method
Number of subjects: 0
Study 18723821 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based (LB) teaching method
Number of subjects: 0
Study 18723821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both teaching methods
Number of subjects: 0
Study 15863374 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (20 microg type 6, 40 microg type 11, 40 microg type 16, and 20 microg type 18) administered at day 1, month 2, and month 6.
Number of subjects: 277
Study 15863374 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparations (two types).
Number of subjects: 277
Study 12787419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow group (Qa <600 mL/min or clinical criteria)
Number of subjects: 101
Study 12787419 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis group (stenosis >50% or clinical criteria)
Number of subjects: 101
Study 12787419 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical criteria)
Number of subjects: 101
Study 12787419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow group
Number of subjects: 101
Study 12787419 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis group
Number of subjects: 101
Study 10540051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U of Botox (Allergan)
Number of subjects: 78
Study 10540051 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 U of Dysport (Ipsen)
Number of subjects: 78
Study 8717471 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Number of subjects: 813
Study 8717471 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Number of subjects: 813
Study 8717471 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue
Number of subjects: 813
Study 8717471 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH analogue
Number of subjects: 813
Study 8717471 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex plus LHRH analogue
Number of subjects: 813
Study 1648598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic-alternating treatment with ifosfamide/etoposide (IE), cyclophosphamide, doxorubicin, and vincristine (CAV)
Number of subjects: 321
Study 1648598 — intervention group
Group type: COMPARATOR
Intervention: Response-oriented treatment with IE therapy up to maximal response and subsequently an immediate switch to CAV
Number of subjects: 321
Study 1648598 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited-stage disease (LD) patients with cyclic-alternating treatment
Number of subjects: 321
Study 1648598 — intervention group
Group type: COMPARATOR
Intervention: Limited-stage disease (LD) patients with response-oriented treatment
Number of subjects: 321
Study 1648598 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive-stage disease (ED) patients with cyclic-alternating treatment
Number of subjects: 321
Study 1648598 — intervention group
Group type: COMPARATOR
Intervention: Extensive-stage disease (ED) patients with response-oriented treatment
Number of subjects: 321
Study 7065957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% epinephrine borate added three hours after 0.5% timolol maleate
Number of subjects: 14
Study 7065957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% epinephrine borate added five minutes after 0.5% timolol maleate
Number of subjects: 14
Study 31834114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube B (MiniONE)
Number of subjects: 158
Study 31834114 — intervention group
Group type: COMPARATOR
Intervention: Tube A (MIC-KEY)
Number of subjects: 158
Study 30129806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nigella sativa and Vitex agnus-castus with citalopram
Number of subjects: 46
Study 30129806 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 46
Study 28810844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 18
Study 28810844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28155305 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for Tanzanian caregiver students in relational communication therapy (RCT)
Number of subjects: 12
Study 25133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body mass
Number of subjects: 176
Study 25133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat mass
Number of subjects: 176
Study 25133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lean mass
Number of subjects: 176
Study 25133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thigh and total abdominal fat
Number of subjects: 176
Study 25133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh fat
Number of subjects: 176
Study 22453077 — intervention group
Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 24
Study 22453077 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation model 1
Number of subjects: 24
Study 22453077 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation model 2
Number of subjects: 24
Study 19118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobe resection (ATLR)
Number of subjects: 16
Study 17449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 0
Study 17449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingencies (reward)
Number of subjects: 0
Study 17449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and contingencies
Number of subjects: 0
Study 17449836 — intervention group
Group type: COMPARATOR
Intervention: Combination of medication and reward
Number of subjects: 0
Study 17449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and response cost
Number of subjects: 0
Study 15057257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg before intercourse
Number of subjects: 30
Study 15057257 — intervention group
Group type: COMPARATOR
Intervention: CPAP during night time sleep
Number of subjects: 30
Study 16459225 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG meal (10 g of DAG oil)
Number of subjects: 43
Study 16459225 — intervention group
Group type: COMPARATOR
Intervention: TAG meal (10 g of TAG oil)
Number of subjects: 43
Study 16459225 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG meal
Number of subjects: 43
Study 16459225 — intervention group
Group type: COMPARATOR
Intervention: TAG meal
Number of subjects: 43
Study 10802151 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg/day
Number of subjects: 24
Study 10802151 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine, 30 mg/day
Number of subjects: 24
Study 8858389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra, UK‐92,480)
Number of subjects: 12
Study 1353368 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg daily
Number of subjects: 40
Study 1353368 — intervention group
Group type: COMPARATOR
Intervention: diazepam 5 mg twice daily
Number of subjects: 40
Study 1353368 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 40
Study 6143631 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 0
Study 6143631 — intervention group
Group type: COMPARATOR
Intervention: ICI 118551 (beta 2 antagonist)
Number of subjects: 0
Study 31573913 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based intervention
Number of subjects: 70
Study 31573913 — intervention group
Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 70
Study 30235680 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based obesity management services for 24 weeks
Number of subjects: 324
Study 30235680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study 27243978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure session with never-used safety behaviour (NU)
Number of subjects: 57
Study 27243978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure session with routinely used safety behaviour (RU)
Number of subjects: 57
Study 27243978 — intervention group
Group type: COMPARATOR
Intervention: Exposure session with no safety behaviour (ERP)
Number of subjects: 57
Study 24559858 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injection at the bladder neck (100 IU)
Number of subjects: 20
Study 24559858 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment (both groups)
Number of subjects: 20
Study 22172443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 744
Study 20620037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg via Respimat inhaler once daily for 48 weeks
Number of subjects: 3991
Study 20620037 — intervention group
Group type: COMPARATOR
Intervention: Placebo via Respimat inhaler once daily for 48 weeks
Number of subjects: 3991
Study 17289892 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg, twice daily starting on day 2 of cycle 1)
Number of subjects: 12
Study 17289892 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (escalated doses of 180, 200, 220, and 260 mg/m2 in FOLFIRI regimen)
Number of subjects: 12
Study 17289892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 15855216 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation at 400 mg/day for 9 months
Number of subjects: 400
Study 15855216 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no vitamin E)
Number of subjects: 400
Study 11939671 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (Kliogest)
Number of subjects: 56
Study 11939671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9571328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (255 mEq of sodium daily)
Number of subjects: 19
Study 9571328 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet (85 mEq of sodium daily)
Number of subjects: 19
Study 7542021 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy in addition to best supportive care
Number of subjects: 61
Study 7542021 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 61
Study 30239824 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 1280
Study 28532471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 54
Study 28532471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25352095 — intervention group
Group type: EXPERIMENTAL
Intervention: MKT alone
Number of subjects: 39
Study 25352095 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser alone
Number of subjects: 39
Study 25352095 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer + MKT
Number of subjects: 39
Study 25352095 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patches)
Number of subjects: 39
Study 24252934 — intervention group
Group type: EXPERIMENTAL
Intervention: BWSTT with power‐assisted functional electrical stimulation
Number of subjects: 30
Study 23120952 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (study arm)
Number of subjects: 3080
Study 23120952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control arm)
Number of subjects: 3080
Study 18518863 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 4116
Study 18518863 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (long-term treatment > 6 months)
Number of subjects: 4116
Study 18518863 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (short-term treatment ≤ 6 months)
Number of subjects: 4116
Study 18518863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4116
Study 16269184 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon α-2b (1.5 μg/kg once weekly) plus ribavirin (800 mg daily) for 48 weeks for HCV genotypes 1/4 and 24 weeks for genotypes 2/3
Number of subjects: 122
Study 15351552 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance plus moderate resistance (MR) training
Number of subjects: 79
Study 15351552 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance plus low resistance (LR) training
Number of subjects: 79
Study 15351552 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training only
Number of subjects: 79
Study 15351552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 11505346 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 100
Study 11505346 — intervention group
Group type: COMPARATOR
Intervention: Conventional extubation
Number of subjects: 100
Study 9006691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of the ligaments as described by Karlsson et al. (Group I)
Number of subjects: 60
Study 9006691 — intervention group
Group type: COMPARATOR
Intervention: Modification of the Broström procedure as described by Gould et al. (Group II)
Number of subjects: 60
Study 9006691 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 60
Study 9006691 — intervention group
Group type: COMPARATOR
Intervention: Group II
Number of subjects: 60